射频消融联合肝动脉介入化疗栓塞治疗肝癌的临床分析  

Clinical analysis of radiofrequency ablation combined with transcatheter arterial chemo-embolization in the treatment of hepatic carcinoma

作　　者：辛业刚 沈柏蕊 

机构地区：[1]邹平县中心医院普外科,滨州256212

出　　处：《国际医药卫生导报》2016年第1期37-39,共3页International Medicine and Health Guidance News

摘　　要：目的探讨射频消融联合肝动脉介入化疗栓塞治疗肝癌的临床疗效。方法收集我院2011年7月至2012年7月收治的80例肝癌患者前瞻性研究且随机分为两组，每组40例，实验组患者给予射频消融联合肝动脉介入化疗栓塞治疗，对照组患者给予单独肝动脉介入化疗栓塞治疗，比较两组患者临床控制效果评价、3年之内存活率、生存期、术后不良反应与并发症情况。结果实验组患者临床控制效果明显优于对照组，差异有统计学意义（P〈0．05）。两组患者1年存活率差异无统计学意义（P〉0．05）；实验组患者2年存活率与3年存活率显著高于对照组（92．5％VS．70．0％，85．0％vs．27．5％），差异有统计学意义（P〈0．01）；实验组患者生存期显著长于对照组[（2．31±0．32）年vs．（1．71±0．26）年]，差异有统计学意义（P〈0．01）。两组患者高热、胆红素升高、腹水、胸水与胆囊炎发生率差异无统计学意义（P〉0．05）。结论射频消融联合肝动脉介入化疗栓塞治疗肝癌的临床疗效显著，且安全性较好，具有借鉴性。Objective To investigate the clinical curative effect of radiofrequency ablation combined with transcatheter arterial chemo-embolization in the treatment of hepatic carcinoma. Methods 80 cases of hepatic carcinoma admitted in our hospital from July 2011 to July 2012 were collected for prospective study, and randomly divided into two groups with 40 cases in each group. Experimental group was treated with radiofrequency ablation and transcatheter arterial cherno-embolization, control group was treated with transcatheter arterial chemo-embolization. Compared the evaluation of clinical control effect, three-year survival rate, survival time, postoperative adverse reactions and complications of two groups. Results The clinical control rate of experimental group was significantly higher than that of control group, with statistically significant difference （P〈0.05）. There was no statistically significant difference in one-year survival rate between two groups （P〉0.05）; two-year survival rate, three-year survival rate of experimental group were significantly higher than those of control group （92.5% vs.70.0%, 85.0% vs.27.5%）, with statistically significant differences （P〈0.01）; the survival time of experimental group was significantly longer than that of control group [（2.31±0.32） year vs.（1.71±0.26） year], with statistically significant difference （P〈0.01）. There were no statistically significant differences in the incidences of hyperpyrexia, increased bilirubin, ascites, hydrothorax and cholecystitis between two groups （P〉0.05）. Conclusion Radiofrequency ablation combined with transcatheter arterial chemoembolization has significant clinical curative effect in the treatment of hepatic carcinoma, with good safety, worthy of clinical practice.

关 键 词：射频消融术 肝动脉介入化疗栓塞 肝癌 控制效果 生存期 

分 类 号：R735.7[医药卫生—肿瘤]